Medical management options for heavy menstrual bleeding, as recommended by NICE, include: Levonorgestrel intrauterine system (LNG-IUS) : Often first-line treatment, reducing menstrual blood loss by up to 95% within 12 months Tranexamic acid : An antifibrinolytic agent taken during menstruation to reduce blood loss by 40-50% (caution if you have a history of blood clots) Non-steroidal anti-inflammatory drugs (NSAIDs) : Such as mefenamic acid, which can reduce flow by 20-30% and help with associated pain (use with caution if you have gastrointestinal, renal or cardiovascular conditions) Combined hormonal contraception : Can regulate cycles and reduce bleeding in suitable candidates Oral progestogens : Taken cyclically or continuously, depending on individual circumstances If you currently use a copper intrauterine device (IUD), this can contribute to heavier periods, and switching to a levonorgestrel IUS might be beneficial
The percentages are less than half of those for GLP-1 users who cited financial strain as a reason for cutting back on these baked food categories
Metabolic Support Semaglutide may improve insulin sensitivity and glucose metabolism, making it relevant for both diabetes and obesity-related research
10.1111/imr.13235 40 TianP.XuZ.GuoJ.ZhaoJ.ChenW.HuangW.et al (2024)
Peripherally administered GLP-1R and GIPR agonists have also been shown to localize in CVOs, with limited labelling in brain regions shielded by the bloodbrain barrier 13,54,55
